Supplementary Information from PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia

Jingfeng Zhou,Danian Nie,Juan Li,Xin Du,Yuhong Lu,Yangqiu Li,Chang Liu,Wei Dai,Yun Wang,Yanli Jin,Jingxuan Pan

DOI: https://doi.org/10.1158/1078-0432.22462455

2023-01-01

Abstract:Supplementary Materialsï¼ŒMethods and Figure Legends

What problem does this paper attempt to address?

Supplemetary Figure S1-S8 from PTEN is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia

Jingfeng Zhou,Danian Nie,Juan Li,Xin Du,Yuhong Lu,Yangqiu Li,Chang Liu,Wei Dai,Yun Wang,Yanli Jin,Jingxuan Pan

DOI: https://doi.org/10.1158/1078-0432.22462449.v1

2023-01-01

Abstract:Figure S1 - Biological and pharmacological inhibition of EZH2 potently dampens growth of IM-sensitive and -resistant CML cells; Figure S2 - GSK126 induces apoptosis in CML cells in a dose- and time-dependent manner; Figure S3 - GSK126 elicits cytochrome c release and mitochondrial damage; Figure S4 - Administration of GSK126 in CML mice reduces LSCs in spleen nucleated cells from CML mice; Figure S5 - Knockdown of EZH2 reduces in vivo LSCs in CML mice; Figure S6 - Pharmacological and biological inhibition of EZH2 in CML mice has minimal effect on LSCs and progenitor cells in BM and spleen nucleated cells from CML mice; Figure S7 - BCR-ABL is not involved in the EZH2 knockdown-enabled PTEN transcriptional elevation; Figure S8 - Knockdown of PTEN weakens the effect of LSCs reduction mediated by silencing EZH2.
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Wenqun Zhong,Zebin Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23907869

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Table S1-S3 from PTEN is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia

Jingfeng Zhou,Dan Nie,Juan Li,Xin Du,Yuhong Lu,Yangqiu Li,Chang Liu,Wei Dai,Yun Wang,Yanli Jin,Jingxuan Pan

DOI: https://doi.org/10.1158/1078-0432.22462446

2023-01-01

Abstract:Table S1 shows the Characteristics of patients with CML; Table S2 shows the sequence of shRNA; Table S3 shows the limiting dilution assay of mouse LT-HSC after shEZH2 treatment
PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia.

Jingfeng Zhou,Danian Nie,Juan Li,Xin Du,Yuhong Lu,Yangqiu Li,Chang Liu,Wei Dai,Yun Wang,Yanli Jin,Jingxuan Pan

DOI: https://doi.org/10.1158/1078-0432.CCR-17-1533

IF: 13.801

2018-01-01

Clinical Cancer Research

Abstract:Purpose: Leukemia stem cells (LSCs) are an important source of tyrosine kinase inhibitor resistance and disease relapse in patients with chronic myelogenous leukemia (CML). Targeting LSCs may be an attractive strategy to override this thorny problem. Given that EZH2 was overexpressed in primary CML CD34 thorn cells, our purpose in this study was to evaluate the effects of targeting EZH2 on CML LSCs and clarify its underlying mechanism. Experimental Design: Human primary CML CD34 thorn cells and retrovirally BCR-ABL-driven CML mouse models were employed to evaluate the effects of suppression of EZH2 by GSK126-or EZH2-specific shRNA in vitro and in vivo. Recruitment of EZH2 and H3K27me3 on the promoter of tumorsuppressor gene PTEN in CML cells wasmeasured by chromatin immunoprecipitation assay. Results: Our results showed that pharmacologic inhibition of EZH2 by GSK126 not only elicited apoptosis and restricted cell growth in CML bulk leukemia cells, but also decreased LSCs in CML CD34 thorn cells while sparing those from normal bone marrow CD34 thorn cells. Suppression of EZH2 by GSK126 or specific shRNA prolonged survival of CML mice and reduced the number of LSCs in mice. EZH2 knockdown resulted in elevation of PTEN and led to impaired recruitment of EZH2 and H3K27me3 on the promoter of PTEN gene. The effect of EZH2 knockdown in the CML mice was at least partially reversed by PTEN knockdown. Conclusions: These findings improve the understanding of the epigenetic regulation of stemness in CML LSCs and warrant clinical trial of GSK126 in refractory patients with CML. Clin Cancer (C) 2017 AACR.
Supplementary Figure Legends from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2

Huafeng Xie,Cong Peng,Jialiang Huang,Bin E. Li,Woojin Kim,Elenoe C. Smith,Yuko Fujiwara,Jun Qi,Giulia Cheloni,Partha P. Das,Minh Nguyen,Shaoguang Li,James E. Bradner,Stuart H. Orkin

DOI: https://doi.org/10.1158/2159-8290.22531206

2023-01-01

Abstract:Supplementary Figure Legends
Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503690

2023-01-01

Abstract:PDF - 71K, Legends for Supplementary Figures 1 through 5.
Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Table from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404374

2023-01-01

Abstract:Supplementary Materials and Methods, Supplementary Figure Legends, and Characteristics of primary human pediatric T-ALL samples (Supplementary Table S1).
Supplementary Figure 1 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404395.v1

2023-01-01

Abstract:Testing the efficacy of combination therapy using small molecules to reduce Pten null leukemia burden and LICs in vivo.
Supplementary Data from SET Domain–Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell Quiescence

Sen Ye,Yan-Fu Ding,Wen-Huan Jia,Xiao-Li Liu,Jing-Yi Feng,Qian Zhu,Sun-Li Cai,Yao-Shun Yang,Qian-Yun Lu,Xue-Ting Huang,Jin-Shu Yang,Sheng-Nan Jia,Guo-Ping Ding,Yue-Hong Wang,Jiao-Jiao Zhou,Yi-Ding Chen,Wei-Jun Yang

DOI: https://doi.org/10.1158/0008-5472.22422729

2023-01-01

Abstract:Supplementary Table S1 and Supplementary Figure S1 to S11
Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Xin Zheng,Xiaolei Fan,Binqing Fu,Ming–Hua Zheng,Aimei Zhang,Kai Zhong,Jun Yan,Rui Sun,Zhigang Tian,Wei H

DOI: https://doi.org/10.1158/0008-5472.22414839.v1

2023-01-01

Abstract:Supplementary Figure 1-6 legends
Supplementary Data from the Hepatic Microenvironment Uniquely Protects Leukemia Cells Through Induction of Growth and Survival Pathways Mediated by LIPG

Haobin Ye,Mohammad Minhajuddin,Anna Krug,Shanshan Pei,Chih-Hsing Chou,Rachel Culp‐Hill,Jessica Ponder,Erik De Bloois,Björn Schniedewind,M.F. Amaya,Anagha Inguva,Brett M. Stevens,Daniel A. Pollyea,Uwe Christians,H. Leighton Grimes,Angelo D’Alessandro,Craig T. Jordan

DOI: https://doi.org/10.1158/2159-8290.22536566

2023-01-01

Abstract:Supplementary figures and information
Supplementary Table 1 from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2

Huafeng Xie,Cong Peng,Jialiang Huang,Bin E. Li,Woojin Kim,Elenoe C. Smith,Yuko Fujiwara,Jun Qi,Giulia Cheloni,Partha P. Das,Minh Nguyen,Shaoguang Li,James E. Bradner,Stuart H. Orkin

DOI: https://doi.org/10.1158/2159-8290.22531203.v1

2023-01-01

Abstract:Figure showing expression of EZH2 in CML and sensitivity of CML cells to EZH2 inhibition.
Supplementary Figure 2 from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2

Huafeng Xie,Cong Peng,Jialiang Huang,Bin E. Li,Woojin Kim,Elenoe C. Smith,Yuko Fujiwara,Jun Qi,Giulia Cheloni,Partha P. Das,Minh Nguyen,Shaoguang Li,James E. Bradner,Stuart H. Orkin

DOI: https://doi.org/10.1158/2159-8290.22531218.v1

2023-01-01

Abstract:Figure showing Ezh2 is required for initiation and development of CML in mouse.
Supplementary Figure 6 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404380

2023-01-01

Abstract:Pten null T-ALL blasts show lower levels of phospho-AKT in response to JQ1 in comparison to LICs.
Supplementary Data from KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs

Fangxue Yan,Jinyang Li,Jelena Milosevic,Ricardo Petroni,Suying Liu,Zhennan Shi,Salina Yuan,Janice M. Reynaga,Yuwei Qi,Joshua Rico,Sixiang Yu,Yiman Liu,Susumu Rokudai,Neil Palmisiano,Sara E. Meyer,Pamela J. Sung,Liling Wan,Fei Lan,Benjamin A. Garcia,Ben Z. Stanger,David B. Sykes,M. Andrés Blanco

DOI: https://doi.org/10.1158/2159-8290.22541240.v1

2023-01-01

Abstract:Supplementary Data from KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs
Supplementary Figure 4 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404386

2023-01-01

Abstract:Sensitivity of primary human pediatric T-ALL cells to rapamycin and JQ1 in vitro.
Supplementary Figure 3 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404389

2023-01-01

Abstract:Cellular and biochemical effects of JQ1 in T-ALL.
Supplementary Figure Legends from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Yajing Liu,Monika L. Burness,Rachel Martin-Trevino,Joey Guy,Shoumei Bai,Ramdane Harouaka,Michael Brooks,Shang Li,Alex Fox,Tahra Luther,April Davis,Trenton L. Baker,Justin A. Colacino,Shawn G. Clouthier,Zhi‐Ming Shao,Max S. Wicha,Suling Liu

DOI: https://doi.org/10.1158/1078-0432.22460774.v1

2023-01-01

Abstract:Supplementary figures 1-8 legends

Supplementary Information from PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia

Supplemetary Figure S1-S8 from PTEN is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Table S1-S3 from PTEN is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia

PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia.

Supplementary Figure Legends from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Table from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 1 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Data from SET Domain–Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell Quiescence

Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Supplementary Data from the Hepatic Microenvironment Uniquely Protects Leukemia Cells Through Induction of Growth and Survival Pathways Mediated by LIPG

Supplementary Table 1 from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2

Supplementary Figure 2 from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2

Supplementary Figure 6 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Data from KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs

Supplementary Figure 4 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 3 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure Legends from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer